Regulation of cytokine signaling by SOCS family molecules

Trends in Immunology

Volumn 24, Issue 12, 2003, Pages 659-666

  Fujimoto, Minoru ^a   Naka, Tetsuji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; CYTOKINE; CYTOKINE INDUCIBLE SRC HOMOLOGY DOMAIN CONTAINING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; PROTEIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING PROTEIN 2; SUPPRESSOR OF CYTOKINE SIGNALING PROTEIN 3; SUPPRESSOR OF CYTOKINE SIGNALING PROTEIN 4; SUPPRESSOR OF CYTOKINE SIGNALING PROTEIN 5; SUPPRESSOR OF CYTOKINE SIGNALING PROTEIN 6; SUPPRESSOR OF CYTOKINE SIGNALING PROTEIN 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGY; AUTOIMMUNITY; CANCER; GENE FUNCTION; GENE OVEREXPRESSION; GENE STRUCTURE; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATORY DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0344440953     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.10.008     Document Type: Review

References (69)

1. Yoshimura A., et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:1995;2816-2826.
2. Endo T.A., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:1997;921-924.
3. Naka T., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:1997;924-929.
4. Starr R., et al. A family of cytokine-inducible inhibitors of signalling. Nature. 387:1997;917-921.
5. Hilton D.J., et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U. S. A. 95:1998;114-119.
6. Kamura T., et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:1998;3872-3881.
7. De Sepulveda P., et al. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J. Biol. Chem. 275:2000;14005-14008.
8. Rui L., et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277:2002;42394-42398.
9. Ungureanu D., et al. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell. Biol. 22:2002;3316-3326.
10. Verdier F., et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J. Biol. Chem. 273:1998;28185-28190.
11. Zhang J.G., et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13261-13265.
12. Nicholson S.E., et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18:1999;375-385.
13. Yasukawa H., et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1999;1309-1320.
14. Narazaki M., et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13130-13134.
15. Nicholson S.E., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6493-6498.
16. Sasaki A., et al. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275:2000;29338-29347.
17. Schmitz J., et al. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:2000;12848-12856.
18. Matsumoto A., et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 89:1997;3148-3154.
19. Ram P.A., Waxman D.J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274:1999;35553-35561.
20. Matsumoto A., et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol. 19:1999;6396-6407.
21. Marine J.C., et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell. 98:1999;617-627.
22. Stoiber D., et al. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-γ J. Immunol. 163:1999;2640-2647.
23. Dalpke A.H., et al. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166:2001;7082-7089.
24. Kinjyo I., et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 17:2002;583-591.
25. Nakagawa R., et al. SOCS-1 participates in negative regulation of LPS responses. Immunity. 17:2002;677-687.
26. Kawazoe Y., et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J. Exp. Med. 193:2001;263-269.
27. Starr R., et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. U. S. A. 95:1998;14395-14399.
28. Naka T., et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15577-15582.
29. Marine J.C., et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 98:1999;609-616.
30. Naka T., et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity. 14:2001;535-545.
31. Alexander W.S., et al. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:1999;597-608.
32. Metcalf D., et al. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc. Natl. Acad. Sci. U. S. A. 99:2002;943-948.
33. Eyles J.L., et al. Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J. Biol. Chem. 277:2002;43735-43740.
34. Fujimoto M., et al. A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo. Int. Immunol. 14:2002;1343-1350.
35. + T cell differentiation. Immunity. 18:2003;475-487.
36. Cornish A.L., et al. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other γc-dependent cytokines in peripheral T cells. J. Biol. Chem. 278:2003;22755-22761.
37. Morita Y., et al. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor α-induced cell death in fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5405-5410.
38. Greenhalgh C.J., et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. 277:2002;40181-40184.
39. Favre H., et al. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 453:1999;63-66.
40. Metcalf D., et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 405:2000;1069-1073.
41. Dey B.R., et al. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J. Biol. Chem. 273:1998;24095-24101.
42. Greenhalgh C.J., et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol. Endocrinol. 16:2002;1394-1406.
43. Cacalano N.A., et al. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat. Cell Biol. 3:2001;460-465.
44. Roberts A.W., et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9324-9329.
45. Seki Y., et al. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13003-13008.
46. Mooney R.A., et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J. Biol. Chem. 276:2001;25889-25893.
47. Krebs D.L., et al. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol. Cell. Biol. 22:2002;4567-4578.
48. Takahashi Y., et al. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 22:2003;372-384.
49. Yasukawa H., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:2003;551-556.
50. Croker B.A., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4:2003;540-545.
51. Lang R., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4:2003;546-550.
52. Niemand C., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 170:2003;3263-3272.
53. Johnston J.A., O'Shea J.J. Matching SOCS with function. Nat. Immunol. 4:2003;507-509.
54. Alexander W.S. Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2:2002;410-416.
55. Berlato C., et al. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J. Immunol. 168:2002;6404-6411.
56. Suzuki A., et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193:2001;471-481.
57. Shouda T., et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108:2001;1781-1788.
58. Takeda K., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 10:1999;39-49.
59. Lovato P., et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J. Biol. Chem. 278:2003;16777-16781.
60. Egan P.J., et al. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J. Clin. Invest. 111:2003;915-924.
61. Seki Y., et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat. Med. 9:2003;1047-1054.
62. Yoshikawa H., et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:2001;29-35.
63. Nagai H., et al. Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis. J. Hepatol. 34:2001;416-421.
64. Galm O., et al. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 101:2003;2784-2788.
65. Yasukawa H., et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111:2003;469-478.
66. Bertholet S., et al. Leishmania donovani-induced expression of suppressor of cytokine signaling 3 in human macrophages: a novel mechanism for intracellular parasite suppression of activation. Infect. Immun. 71:2003;2095-2101.
67. Bode J.G., et al. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17:2003;488-490.
68. Sakamoto H., et al. A Janus kinase inhibitor, JAB, is an interferon-γ-inducible gene and confers resistance to interferons. Blood. 92:1998;1668-1676.
69. Sakai I., et al. Constitutive expression of SOCS3 confers resistance to IFN-α in chronic myelogenous leukemia cells. Blood. 100:2002;2926-2931.